No, it's legit.

lol ok great, then don't! No big deal. Move on to better things. Why are you posting here?

ok, good bye!

PharmaDrug reveals positive research results for cepharanthine in the treatment of multiple cancers

Mine just switched over too!

I asked them about this before with another stock. This is what they told me:

"Whenever a security undergoes a split or exchange into a new name/symbol, accounts are updated as soon as the depository allocates the new shares to our clearing firm. Allocation is usually done once the depository receives the new shares from the company. Regarding XXXX updating in your account with the new shares, we currently do not have an anticipated swing date provided by the issuer when we will receive the new shares. However, as soon as we receive the new shares, the position will automatically be updated in your account and reflect back under the ticker XXXX.

This was a Mandatory Reorganization per the company, so there is no action that you had to take and your account updated automatically. At TD Ameritrade we do not front the shares, meaning we do not post them into accounts until they have been allocated. We appreciate your patience while we are waiting to allocate the shares. Again, as soon as we receive the new shares they will be updated in your account and allocation can occur throughout the day as well."

So, basically our shares will automatically change once the company gives them to the depository. I heard Fidelity changed theirs already. TD's will probably change tomorrow. Village Farms got halted by the NASDAQ 2 years ago because of something similar.

Here's some Unrivaled Korova product I bought in San Diego 2 years ago. They're a popular brand and they're all over Cali, so I was excited when Terra Tech announced the merger. Even more excited that they've changed the Company and ticker name!

The shares you already own will change within a few days. Probably by tomorrow.

Let's all vote for Pharmadrug and help get some eyes on us!

Poll 1(March) - https://strawpoll.com/k9xagoz85

Poll 2(June 6th) - https://strawpoll.com/ru8qhfqcb/

Pharmadrug Completes Strategic Mutual Investment with Red Light Holland Corp.

https://money.tmx.com/en/quote/BUZZ:CNX/news/6232590938629960/Pharmadrug_Inc_Completes_Strategic_Mutual_Investment_with_Red_Light_Holland_Corp

Toronto, Ontario--(Newsfile Corp. - July 16, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the "Company") is pleased to announce that it has completed the share exchange transasction with Red Light Holland Corp. ("RLH") (CSE: TRIP) (FSE: 4YX), an Ontario-based corporation positioning itself to engage in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, announced in the Company's July 16, 2020 press release.

Under the terms of the agreement, the Company issued 9,333,333 units to RLH (the "PharmaDrug Units") at a price of $0.075 per PharmaDrug Unit, and RLH issue 4,242,424 units (the "RLH Units") to the Company. Each PharmaDrug Unit consists of (i) one common share of PharmaDrug, (ii) 0.9 of a PharmaDrug common share purchase warrant, with each whole warrant entitling the holder thereof to acquire one common share of the Company at a price of $0.13 until July 16, 2024, and (iii) 0.1 of a PharmaDrug common share purchase warrant, with each whole warrant entitling the holder thereof to acquire one common share of PharmaDrug at a price of $0.08 until July 16, 2024. In addition, RLH subscribed for $200,000 of units of the Company, at a price of $0.075 per unit, with each unit consisting of (i) one common share of PharmaDrug, and (ii) one PharmaDrug common share purchase warrant, with each warrant entitling the holder thereof to acquire one common share of PharmaDrug at a price of $0.08 until July 16, 2024.

Each RLH Unit consists of one common share in the capital of RLH (a "RLH Share") and one RLH Share purchase warrant (a "RLH Warrant"). Each RLH Warrant entitles the holder to purchase one additional RLH Share at an exercise price of $0.26 at any time until July 16, 2024, subject to an accelerated expiry option. If, following the date that is four months and one day following the date hereof, the volume weighted average trading price of the RLH Shares on the Canadian Securities Exchange (the "CSE") for any 10 consecutive trading days equals or exceeds $0.50, RLH may, upon providing written notice to the holders of RLH Warrants, accelerate the expiry date of the RLH Warrants to the date that is 30 days following the date of such written notice.

The Company intends to use the proceeds of the $200,000 investment for working capital and general corporate purposes.

All securities of the Company issued pursuant to the above transaction are subject to a four-month hold period under applicable securities laws expiring four months and one day after the closing.

About PharmaDrug Inc.

PharmaDrug Inc. is building an international controlled substance and natural medicine company with a focus on Europe. The Company owns 80% of Pharmadrug GmbH, a German medical cannabis distributor, with a Schedule I European Union narcotics license allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the EU. The Company also owns 100% of Super Smart, an early-stage retail company focused on consolidating the fragmented Dutch smartshop market. Smartshops are retail establishments in The Netherlands that specialize in the sale of psychoactive substances including psychedelic truffles.

For further information, please contact:

Daniel Cohen, Chairman and CEO
dcohen@pharmadrug.co
(647) 202-1824

PharmaDrug's Super Smart Reaches Distribution Agreement with Red Light Holland for iMicrodose Packs and for Red Light Holland to Build out an iMicrodose Media Information Centre (iMIC) with Super Smart's Location in Tiel, The Netherlands

https://money.tmx.com/en/quote/BUZZ:CNX/news/4730089652586082/PharmaDrugs_Super_Smart_Reaches_Distribution_Agreement_with_Red_Light_Holland_for_iMicrodose_Packs_and_for_Red_Light_Holland_to_Build_out_an_iMicrodose_Media_Information_Centre_iMIC_with_Super_Smarts_Location_in_Tiel_The_Netherlands

Toronto, Ontario--(Newsfile Corp. - September 28, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC PINK: LMLLF) ("PharmaDrug" or the "Company") is pleased to announce that its wholly-owned subsidiary Interrobang Ltd. (doing business as Super Smart) ("Super Smart") has reached a distribution agreement with Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC:TRUFF) (Red Light Holland") for Red Light Holland's iMicrodose Packs ("iMicrodose Packs"). The iMicrodose Packs are expected to be available in Super Smart's first Slim Winkel store, located in Tiel, in early October 2020.

Red Light Holland has also definitively agreed to build and set up an iMicrodose Media Information Centre ("iMIC") in Super Smart's Tiel location, expected to be ready before the end of 2020.

"Super Smart's vision and iMicrodose's vision truly align." Said Todd Shapiro, CEO and Director of Red Light Holland. "Both Companies are focused on educating, informing and modernizing the psychedelic industry within the Netherlands. We are very excited to soon have another Store where our product is sold to expand our marketplace. Equally as important, we are proud to set up our first iMicrodose Media Information Centre - iMIC - where we will eventually provide Super Smart with our Virtual Reality Headset where consumers can truly learn about our iMicrodose packs and the origins of the product, as well as receive important customer feedback, as we want to give all consumer's a voice for important information gathering and responsible use feedback via our iMIC activation."

"Red Light Holland has definitely already taken initial steps to modernize the industry in the Netherlands and we are so pleased to house their responsible use product in our Tiel location, expected in early October 2020." Added Daniel Cohen, CEO and Chairman of PharmaDrug. "Together we want to elevate the industry, educate consumers and intelligently target all Adult Demographics for potential increased sales via new customers with an informational, technological and modern approach."

Super Smart's Tiel location is located in Central Netherlands and is the only smart shop within a 75 Kilometre radius. iMicrodose Packs powered by Red Light Holland are expected to be in Super Smart's Tiel store in October 2020.

About Red Light Holland Corp.

The Company is an Ontario-based corporation positioning itself to engage in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal, recreational market within the Netherlands, in accordance with the highest standards, in compliance with all applicable laws.

For additional information on the Company:

Todd Shapiro
Chief Executive Officer & Director
Tel: 647-204-7129
Email: todd@redlighttruffles.com
Website: https://redlighttruffles.com/

About PharmaDrug Inc.

PharmaDrug Inc. is building an international controlled substance and natural medicine company with a focus on Europe. The Company owns 80% of Pharmadrug GmbH, a German medical cannabis distributor, with a Schedule I European Union narcotics license allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the EU. The Company also owns 100% of Super Smart, an early-stage retail company focused on consolidating the fragmented Dutch smartshop market. Smartshops are retail establishments in The Netherlands that specialize in the sale of psychoactive substances including psychedelic truffles.

For further information, please contact:

Daniel Cohen, Chairman and CEO
dcohen@pharmadrug.co
(647) 202-1824

Why is the company name spelled wrong for this board? No wonder I could never find it.

Hope you guys can take a look at Red Light's sister company PharmaDrug(OTC:LMLLF CSE:BUZZ). Much of Red Light's EU mission involves PharmaDrug. I think PharmaDrug's a possible merger target for Red Light/Creso.

Bought this for the 1st time this morning on TD Ameritrade. In at .0003, out at .0014. THANK YOU SEC!

Will put my profits into a reputable psychedelic company - Pharmadrug.

Great day and great close! That news story's been taken down. So either it was an unofficial leak? or EVIO asked them to take it down? Maybe we get an official 8K tomorrow?

I just sold. Took a big percentage loss. Didn't have much invested at all, so oh well. Bought in on the Arizona Tea deal. Horribly run and now they're talking about a CTO smh, no thanks. Good luck to the you and everyone!

ABSOLUTE GARBAGE

Lol

Great news and the market agrees. Volume is great today.

But nothing to do with OPTI, correct? thank you.

I don't see OPTI mentioned here anywhere. There's nothing even remotely pertaining to OPTI in your post. This is from 14 years ago! This is nonsense spam.

PharmaDrug Provides Update on Its Annual General Meeting

Toronto, Ontario--(Newsfile Corp. - March 12, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink:LMLLF) ("PharmaDrug" or the "Company"), will hold its Annual General Meeting ("AGM" or "Meeting") on March 25, 2021 at 10:00AM Eastern Standard Time at its corporate office, Suite 2905 - 77 King Street West, Toronto. The call-in number for the Meeting is 1-855-473-1059 and the access #0091269.

In light of the ongoing COVID-19 situation, the Company strongly encourages registered shareholders and proxyholders not to attend the AGM in person, and Shareholders are encouraged to vote using one of the methods described in the Management Information Circular ("MIC") which can be viewed on SEDAR. The Meeting can be accessed by conference call. This call will be listen-only and shareholders will not be able to vote or speak at, or otherwise participate in the Meeting via the conference call. The Corporation's board of directors and auditors do not plan to attend the Meeting in person.

Yup, vol was great. Touched .087usd(.11cad) today. Sentiment on different boards is great. Let's see if the Canadians can push it to .15cad.

ahh ok, thanks. I'll probably be all out by then lol. Did you buy back in on the dips before Canadians started trading on Friday or you looking for more punishment? lol. All jokes aside, the COVID medication sounds good tho, sounds alot like that Relief Therapeutics play that was hot over the summer.

Yeah they're gonna change the ticker along with the name. Check this morning's NR on SEDAR.

And a new name or cusp ID isn't a call for a RS. Two totally different things. I don't recall them doing a RS when they changed their OTC ticker from QUEZF to KALTF.

Oh, I didn't mean today. Shoulda clarified. It didn't go to .10 on the US side on the first day. It was like 2-3 days of trading first.

The Canadians started trading today. With their volume and action we could see .12 today.

The new website is live as well. https://claritaspharma.com/

Great news!

BUZZ vol is looking great today. PharmaDrug's definitely being noticed!

Watching the progression has been great! We went from less than 500k daily to over 7M each of the last two days. Amazing.

This stock doesn't exist in a vacuum. It tanked because big money is watching idiots broadcast their moves online and they're acting accordingly. It went up fast and tanked down fast. Oh well, we're right back where we were.

With a strong brand and established supply chain in Germany, meet the team leading our expansion in the potential €58 billion Euro Cannabis market | $BUZZ

Learn more: https://bit.ly/3d0EecF

With a strong brand and established supply chain in Germany, meet the team leading our expansion in the potential €58 billion Euro Cannabis market | $BUZZ

Learn more: https://t.co/kCpfjVaZDd #cannabis #EU

— Pharmadrug | CSE: PHRX (@Pharmadrug_Inc) February 12, 2021

From Marijuana To Magic Mushrooms: Harry Resin Has 'Cutting Edge' Psychedelic Plans

https://www.benzinga.com/markets/cannabis/20/05/16131724/from-marijuana-to-magic-mushrooms-harry-resin-has-cutting-edge-psychedelic-plans

For Harry Resin, working in the cannabis industry has been quite a trip.

After spending some two decades growing, breeding and writing about pot, the 44-year-old entrepreneur now has his sights set on another niche industry — psychedelics.

Resin, an early inductee into the High Times Seed Bank Hall of Fame, recently inked a deal between his startup — Super Smart — and Pharmadrug Inc., a medicinal research company based in Toronto.

Terms of the deal were not disclosed, but Resin revealed to Benzinga tons of background info on the transaction and the combined company's strategy going forward.

"The approach we are trying to take is to eliminate the stigma associated with magic mushrooms," Resin told me. "By having one-on-one consultations with our customers, we will be able to educate them and offer them a more informed experience."

Below, Oakland-based Resin chats about the "party drug" stigma surrounding psychedelics, his plan to bring "cutting edge" products to market, and why "microdosing" with mushrooms will eventually become mainstream.

BZ: How did the merger with Pharmadrug come about?
HR: I’ve been active in the cannabis sector for a long time and was approached by some investors in Canada to spearhead this new project. They came to me for my years of experience working in Amsterdam.

With my experience as a supply chain coordinator for many of the Dutch coffeeshops, I have a unique understanding of working in a deeply regulated sector like the Dutch smart shop industry. Many of my contacts are involved in that industry so it was a natural fit. This is what led me to the team and putting the SuperSmarty deal together. By luck, an old friend of mine's husband was the CEO of Pharmadrug and we got to talking. One thing led to another and we had a deal.

What made it a great fit?
It’s a great fit because with Pharmadrug’s license, we will have a two-pronged approach: The smart shops in the Netherlands will allow us to build a recreational model selling magic mushrooms, while Pharmadrug will allow us to import alternative plant-based medicine to pharmacies throughout Europe.

Do you still write, or did you transition completely to being CEO of Super Smart?
I still write and I’m still active in cannabis. I pride myself on being at the forefront of industries making the leap from the counter culture to the mainstream. So for me there was a natural evolution with cannabis and psilocybin.

Additionally, the work we are currently doing in cannabis with extraction technology and water solubility will drive product development and brand building in the psilocybin space. By having a retail presence in a legal market like the Netherlands, we will be on the forefront of releasing new products in the space. We are going to work with a strong advisory board in order to also help develop new products in the space. All of which we can test in the legal market in the Netherlands.

Like cannabis, there's a stigma attached to psychedelics – at least in the U.S. What should skeptics know?
As with cannabis we need to look beyond the stigma and beyond the false information circulated during the global “war on drugs.” Psilocybin is currently going through a renaissance because more and more people are realizing it can be used medicinally rather than solely as a party drug. There are currently many studies being undertaken looking at the mental health benefits of microdosing and its become something very popular in the world of nootropics.

2020 has been a troublesome year for small business owners. What trends do you expect to see for the remainder of the year, and heading into 2021?
I see a combination of consolidation and more curated retail experiences. By interacting more intimately with customers and limiting the amount of customers coming into stores at one time, it will fulfill both the role of social distancing and of a more curated experience. The approach we are trying to take is to eliminate the stigma associated with magic mushrooms and by having one-on-one consultations with our customers, we will be able to educate them and offer them a more informed experience.

What about the industry surprises you?
I'd say the scientific advances are what probably surprised me the most. To go from smoking hand-rubbed hash and cannabis flower to dabbing THCA diamond crystals bathed in terpene juice is something else. That's what excited me the most about psychedelics. It becomes the 'what next.'

With our connections and my cannabis experience, we plan on being on the cutting edge of new products in the psychedelic space. Dosing eventually will be a crucial aspect of using the plant as medicine with replicable results. Therefore extracting psilocybin and developing new novel methodologies with which to use that extraction excite us and will be an important part of the future.

Any advancements so far?
Truthfully I was able to make rudimentary ethanol extraction that was dabbable and the effect was interesting. Stronger than a cannabis oil dab, but not quite hallucinogenic. This idea of microdosing and curating experience will be an interesting concept to play within the space. By having the strong retail arm in the Netherlands, we will have a vast sea with which to explore all the possibilities of new products and their interactions with our customers. We will also track our customers' effects through questionnaires so that we can collect as much data as possible in an empirical way when it comes to product efficacy. This will also help us shape the future of the psychedelic industry and what will collectively come up with as the next advancement. To me that's really exciting.

What lessons did you learn over the years?
The lesson I’ve learned is that acceptance is possible. I never thought that the counter culture would reach the mainstream. It's great to see these plants and fungi that have been evolving alongside humanity — finally get the respect they deserve.

PharmaDrug updated the share count on the LMLLF OTC page

https://www.otcmarkets.com/stock/LMLLF/security

Now we're current with the CSE page.

Share Structure:
Market Cap Market Cap = 26,069,039 02/10/2021
Authorized Shares = Not Available
Outstanding Shares = 325,862,983 02/09/2021

PharmaDrug Files for FDA Orphan Drug Designation for DMT in Stroke

https://www.newsfilecorp.com/release/74241/PharmaDrug-Files-for-FDA-Orphan-Drug-Designation-for-DMT-in-Stroke

Toronto, Ontario--(Newsfile Corp. - February 11, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce it has filed an application with the U.S. Food and Drug Administration ("FDA") to receive Orphan Drug Designation ("ODD") for N,N-Dimethyltryptamine ("DMT") in the treatment of acute ischemic stroke patients presenting for emergency medical assistance within 3-hours of symptom onset.

Acute ischemic stroke is characterized by the sudden loss of blood circulation to an area of the brain, resulting in a corresponding loss of neurologic function. Around 85% of all strokes are due to a blockage cutting off the blood supply to the brain. Stroke-related costs in the United States were approximately $46 billion between 2014 and 2015. (Source: CDC).

In pre-clinical research, DMT has been shown to improve ischemic brain injury in rats, both by decreasing brain lesion volume and by improving subsequent motor function recovery. Following acute ischemic stroke DMT activates the sigma-1 receptor (Sig-1R) and critical downstream pathways known to enhance production of anti-stress and antioxidant proteins; the impact of which, specifically diminishes the deleterious impact of hypoxia and oxidative stress to brain cells. Restoration of blood flow to affected regions of the brain through administration of tissue plasminogen activator (tPA aka alteplase), long considered gold-standard treatment for ischemic stroke, often only partially rescues damaged brain regions. As such, the development of novel approaches to treat ischemic stroke, such as PharmaDrug's DMT program, represent a critical development in reducing patients resulting neurological deficit.

"We are building an industry-leading foundation to explore the clinical potential of DMT in rare neuropsychiatric and neurological disorders. With the submission of our orphan drug application to the FDA now complete we will move swiftly to accelerate the research and development of DMT for acute ischemic stroke," said Daniel Cohen, CEO of PharmaDrug. "Additionally, we will continue to broaden our DMT clinical programs by taking advantage of valuable FDA regulatory incentives such as orphan drug, fast track and breakthrough therapy designations."

The Company's psychedelic pharmaceutical strategy will focus on DMT by expanding its product pipeline through licensing, pre-clinical and clinical research, forming research collaborations with academic institutions and industry, broadening its intellectual property portfolio with unique formulations, development of novel uses and delivery systems, and by adding medical and clinical experts to its scientific advisory board.

The Orphan Drug Act grants special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor. This status is referred to as orphan designation (or sometimes "orphan status"). The FDA grants ODD status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics. The FDA defines rare diseases as those affecting fewer than 200,000 people in the United States at any given time. ODD would qualify DMT for certain benefits and incentives, including seven years of marketing exclusivity if regulatory approval is ultimately received for the designated indication, potential tax credits for certain clinical drug testing costs, activities, eligibility for orphan drug grants, and the waiver of the FDA New Drug Application filing fee of approximately USD $2,400,000.

Yeah guys, let's not get into the habit of comparing PPS. Gotta compare market cap. CRON was in the 4s in March 2020. No dilution, no capital raises, no closed facilities(except OGBC which they sold), no ridiculous "double diamond" "platinum sky" halted construction projects, no layoffs and NO RS! ACB had done ALL of the above at several times last year.

Ask a long time ACBFF holder what they think of their ACB shares nowadays lol. That last RS killed them. ACB is great if you bought in for the first time in the last few months. That's about it.

Wow a positive MF article! OMG.. possibly, first one in 5 years?

Wow...you mean an OTC stock got suspended?! Wow! Big news! In other "news", the sky is blue!

OPTI is top notch. I got in on the run from .02s to .30s! I'm paying for an extension on my house with OPTI gains!!

Thanks, I have some pretty great connections with the SEC over the years. I just asked my good friend at the SEC about these supposed bi weekly meetings. She wants to know what office and she says you're probably making that story up out of thin air or maybe even a tv show. I asked her about OPTI and she said OPTI isn't on their radar and we're good to go!

Nah, the house is adding an extension and getting bigger! That's what we've all been seeing.

5 minutes till close, we were at .0915(.12cad) but we closed at .081(.1cad). Canadians just won't let this close above .10cad smh.